HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Charcot-Marie-Tooth disease type 4J — Clinical Guidelines

Overview

Charcot-Marie-Tooth disease type 4J (CMT4J) is a hereditary peripheral neuropathy characterized by progressive muscle weakness, atrophy, and sensory loss due to genetic mutations affecting peripheral nerve function 1.

Diagnosis

Clinical Presentation: Common phenotype includes distal muscle weakness and atrophy, sensory loss, and gait disturbances 1 2.

Neurophysiological Studies: Essential for confirming diagnosis; includes nerve conduction studies and electromyography 2.

Genetic Testing: Sequential approach recommended; next-generation sequencing considered after excluding common mutations like PMP22 duplication 2.

Management

Symptomatic Treatment: Focus on managing symptoms such as pain, muscle cramps, and orthopaedic complications; physical therapy and orthoses are commonly utilized 1 2.

Pharmacological Management: No disease-modifying pharmacological treatments available; symptomatic relief may involve analgesics and muscle relaxants as needed 2.

Multidisciplinary Care: Involves neurologists, physiatrists, orthopaedic surgeons, and geneticists to address diverse aspects of the disease 2.

Special Populations

Pediatrics: Early diagnosis crucial; motor nerve conduction abnormalities may evolve over the first 3-5 years of life in hereditary forms 9.

Comorbidities: Caution advised with neurotoxic medications like vincristine and possibly paclitaxel in CMT patients 3.

Key Recommendations

Clinical Assessment Followed by Neurophysiological Studies: Essential for diagnosis; includes nerve conduction studies and electromyography (Evidence: Strong 2).

Sequential Genetic Testing: Rule out common mutations first, then consider next-generation sequencing (Evidence: Moderate 2).

Avoid Neurotoxic Medications: Exercise caution with drugs like vincristine and paclitaxel due to potential exacerbation of neuropathy (Evidence: Moderate 3).

References

1 . Charcot-Marie-Tooth disease and related neuropathies. Nature reviews. Disease primers 2026. link 2 Sivera Mascaró R, García Sobrino T, Horga Hernández A, Pelayo Negro AL, Alonso Jiménez A, Antelo Pose A et al.. Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease. Neurologia 2025. link 3 Cavaletti G, Forsey K, Alberti P. Toxic medications in Charcot-Marie-Tooth patients: A systematic review. Journal of the peripheral nervous system : JPNS 2023. link 4 Inman E. Living With Charcot-Marie-Tooth, Charlie, and Change. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 2020. link 5 Ohshita N, Oka S, Tsuji K, Yoshida H, Morita S, Momota Y et al.. Anesthetic Management of a Patient With Charcot-Marie-Tooth Disease. Anesthesia progress 2016. link 6 Mason MC. Message of hope. Nursing standard (Royal College of Nursing (Great Britain) : 1987) 2008. link 7 Nadal MA, Lago NR, Olivieri LE, de Rosa G, Pierri T. Fibrillary glomerulonephritis and Charcot-Marie-Tooth disease. American journal of kidney diseases : the official journal of the National Kidney Foundation 1998. link70150-7) 8 Lowry PJ, Littler WA. Peroneal muscular atrophy associated with cardiac conducting tissue disease: further observations. Postgraduate medical journal 1983. link 9 Gutmann L, Fakadej A, Riggs JE. Evolution of nerve conduction abnormalities in children with dominant hypertrophic neuropathy of the Charcot-Marie-Tooth type. Muscle & nerve 1983. link 10 Manyam NV, Cowell HR, Katz L. Charcot-Marie-Tooth disease and schizophrenia in identical twins. JAMA 1979. link

Charcot-Marie-Tooth disease type 4J